In various pre‐clinical models of peripheral nerve injury, the intrathecal administration of neutralizing antibodies against either FKN or CX3CR1 have been found to delay or attenuate chronic pain‐associated behaviours (Milligan et al. The gene discussed is CX3CL1; the disease is peripheral nerve injury.